Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Phase 1/2a Clinical Trial to Begin in Second Half of July

15-Jun-2020 - Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is ...

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

27-Aug-2014 - Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology ...

Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)

05-Jul-2012 - The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International NV ...

Discontinuation of sale of ceftobiprole in Switzerland

13-Sep-2010 - Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authorization ...

European CHMP concludes re-examination of ceftobiprole

29-Jun-2010 - Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing ...

European CHMP adopts negative opinion on ceftobiprole

23-Feb-2010 - Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The sponsor ...

INTELENCE (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy

02-Sep-2008 - The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCE(TM) (etravirine). INTELENCE is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) showing efficacy in patients with NNRTI-resistant HIV. Also known as TMC125, ...

Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole

19-Jun-2007 - Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment ...